Jerjen R, Meah N, de Carvalho LT, et al. - Researchers conducted this retrospective study to assess the use of oral tofacitinib in pre‐adolescent patients with alopecia areata (AA). Between 2018 and 2019, case records of all pre‐adolescent patients with AA treated with oral tofacitinib in a single center were analyzed. Fourteen patients, aged 7 to 11 years, were identified. According to results, three patients obtained full remission [Severity of Alopecia Tool (SALT) score of 0], seven (63.6%) obtained over 50% improvement in SALT score from baseline. Findings suggested that tofacitinib plays a role in AA as systemic therapy and this should be further tested in prospective pre-adolescent clinical trials.